RxDoctor Payments DataLook up a doctor →

Luis Rojas, APRN

Family · Bridgeport, CTNPI 1487785838

Payments from drug & device makers

$21,613in general payments, 2019–2025

Across 787 payments — averaging $27.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Novo Nordisk$3K
  • AbbVie$2K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$1K
  • Amgen$1K
  • plus $10K from 44 others

What the payments were for

  • Food & beverage$21,39199%
  • Education$2221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,613 in reported general payments places this provider in the 95th percentile of 1,596 family providers in Connecticut.

See all family providers in Connecticut

Medicare billing

Part B allowed, 2024
$46,908
Medicare patients
75
Services billed
712

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide143$148,296
JardianceEmpagliflozin127$148,065
OzempicSemaglutide103$109,052
RybelsusSemaglutide51$100,349
FarxigaDapagliflozin Propanediol70$83,715
JanuviaSitagliptin Phosphate23$26,289
TrulicityDulaglutide23$23,066
ZtlidoLidocaine47$17,760
VascepaIcosapent Ethyl34$17,664
Tresiba Flextouch U-100Insulin Degludec28$17,299
Janumet XrSitagliptin Phos/Metformin Hcl29$15,654
SymbicortBudesonide/Formoterol Fumarate60$15,557
Breo ElliptaFluticasone/Vilanterol35$14,469
JanumetSitagliptin Phos/Metformin Hcl12$11,816
Fluticasone-SalmeterolFluticasone Propion/Salmeterol44$9,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,592$209,401154 claims
AbbVieLinzess$1,521$148,296143 claims
Boehringer IngelheimJardiance$1,449$148,065127 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$3,298$105,355141 claims
MerckJanuvia, Janumet Xr, Janumet$351$53,75864 claims
Lilly USA, LLCTrulicity$1,428$23,06623 claims
Scilex Pharmaceuticals Inc.Ztlido$244$17,76047 claims
GSKBreo Ellipta$1,102$14,46935 claims
Arbor Pharmaceuticals, Inc.Edarbi$27$7,06811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,596 family providers in Connecticut.

Other family in Bridgeport

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →